Cytosorbents FY2025 EPS Forecast Lifted by HC Wainwright

Cytosorbents Co. (NASDAQ:CTSO - Free Report) - Research analysts at HC Wainwright increased their FY2025 earnings per share estimates for shares of Cytosorbents in a research report issued to clients and investors on Thursday, May 15th. HC Wainwright analyst S. Lee now expects that the medical research company will post earnings of ($0.19) per share for the year, up from their previous forecast of ($0.24). HC Wainwright has a "Neutral" rating and a $1.00 price target on the stock. The consensus estimate for Cytosorbents' current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cytosorbents' Q4 2025 earnings at ($0.06) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.14) EPS, FY2028 earnings at ($0.10) EPS and FY2029 earnings at ($0.09) EPS.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last issued its earnings results on Wednesday, May 14th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The company had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.01 million.

A number of other equities research analysts have also commented on the company. StockNews.com assumed coverage on Cytosorbents in a research report on Tuesday, May 13th. They set a "hold" rating on the stock. D. Boral Capital restated a "buy" rating and set a $10.00 target price on shares of Cytosorbents in a report on Thursday.

Cytosorbents Stock Performance

NASDAQ CTSO opened at $0.90 on Monday. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $1.61. The company has a 50 day moving average of $1.00 and a 200-day moving average of $0.99. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The firm has a market cap of $56.35 million, a price-to-earnings ratio of -2.50 and a beta of 1.17.

Institutional Trading of Cytosorbents

Several hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. lifted its holdings in Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company's stock worth $63,000 after buying an additional 37,519 shares in the last quarter. Avenir Corp boosted its holdings in Cytosorbents by 63.1% in the first quarter. Avenir Corp now owns 5,044,918 shares of the medical research company's stock valued at $5,045,000 after acquiring an additional 1,950,972 shares during the last quarter. CM Management LLC increased its position in Cytosorbents by 36.3% in the first quarter. CM Management LLC now owns 954,076 shares of the medical research company's stock worth $954,000 after purchasing an additional 254,076 shares during the period. Skylands Capital LLC raised its holdings in Cytosorbents by 7.9% during the 1st quarter. Skylands Capital LLC now owns 3,002,702 shares of the medical research company's stock worth $3,003,000 after purchasing an additional 221,080 shares during the last quarter. Finally, Key Client Fiduciary Advisors LLC lifted its position in Cytosorbents by 127.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock valued at $78,000 after purchasing an additional 43,900 shares during the period. 32.87% of the stock is owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.